18. Trade and other receivables and other current assets
|
31 December |
|
|---|---|---|
(thousands of €) |
2021 |
2020 |
Non-current trade receivables |
- |
50,000 |
Trade receivables |
91,786 |
134,632 |
Prepayments |
202 |
219 |
Other receivables |
19,349 |
13,568 |
Trade and other receivables |
111,337 |
148,418 |
Consumables inventory |
- |
319 |
Accrued income |
639 |
1,096 |
Deferred charges |
9,306 |
10,502 |
Other current assets |
9,945 |
11,917 |
Total trade and other receivables & other current assets |
121,282 |
210,335 |
Non-current and current trade and other receivables decreased primarily due to the outstanding receivable as at 31 December 2020 of €160.0 million on Gilead related to the renegotiated agreement of December 2020 for filgotinib, for which we received payments in 2021 of €110 million (a receivable of €50 million being still outstanding on 31 December 2021 and expected to be received in the first quarter of 2022). Additionally, we also recorded a receivable of €12.6 million ($15 million) from Gilead following the agreement for the take-over by us of the DIVERSITY clinical trial. We refer to note 2 Summary of significant transaction for more details.
We consider that the carrying amount of trade and other receivables approximates their fair value.
The other current assets mainly included accrued income from subsidy projects and deferred charges.
On 31 December 2021, we did not have any provision for expected credit losses.